Ok the NYAS slide shows HR = 1.01 for Minimal Residual Disease (near-total resections). Neutral. Median OS was basically the same (20.3 vs 20.4 mos). But the real signal is in Significant Residual Disease – HR ~0.65 with clear survival gain – and in the overall newly diagnosed group (HR = 0.80) plus the strong long-tail survivors.
Not every subgroup benefits, but the aggregate effect + tail is what MHRA will weigh under their RWD framework.
Next time just freaking quote /cite the source for peat's sake will ye? Thats not the first time you do that
Market Data 
Markets 
AI
